Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Egevad

Showing results (91-100 of 379) with videos related to

Pageof 38
Sort By:
The Prostate|July 21, 2004
Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancerAlexander Valdman, Xiaolei Fang, See-Tong Pang, et al.
Scandinavian Journal of Urology and Nephrology|November 30, 2006
Prediction of percent Gleason grade 4/5 by multiple core biopsiesAxel Glaessgen, Christer Busch, Mona Norberg, et al.
Pathology International|September 3, 2011
Solitary fibrous tumor of the prostate: a report of two casesHeidi Talvitie, Kristina Aström, Olle Larsson, et al.
Pathology International|April 14, 2025
The Role of Artificial Intelligence in the Evaluation of Prostate PathologyLars Egevad, Andrea Camilloni, Brett Delahunt, et al.
Pathology|October 19, 2020
Benign mimics of prostate cancerLars Egevad, Brett Delahunt, Bungo Furusato, et al.
European Urology|January 15, 2018
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test PotentialPeter Ström, Tobias Nordström, Markus Aly, et al.
Carcinogenesis|May 23, 2002
Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factorsKari Hemminki, Yongwen Jiang, Xin Ma, et al.
Virchows Archiv : an International Journal of Pathology|April 10, 2003
Overexpression of IGBFB2 is a marker for malignant transformation in prostate epitheliumElin Richardsen, Tanja Ukkonen, Tone Bjørnsen, et al.
Analytical and Quantitative Cytology and Histology|May 1, 2009
Expression of immunomodulating genes in prostate cancer and benign prostatic tissueAnca Reschner, Helena Harlin, Brett Laven, et al.
BJU International|July 24, 2014
Upper limit of cancer extent on biopsy defining very low-risk prostate cancerOla Bratt, Yasin Folkvaljon, Stacy Loeb, et al.
Pageof 38

Showing results (91-100 of 379) with videos related to

Sort By:
Pageof 38
The Prostate|July 21, 2004
Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancerAlexander Valdman, Xiaolei Fang, See-Tong Pang, et al.
Scandinavian Journal of Urology and Nephrology|November 30, 2006
Prediction of percent Gleason grade 4/5 by multiple core biopsiesAxel Glaessgen, Christer Busch, Mona Norberg, et al.
Pathology International|September 3, 2011
Solitary fibrous tumor of the prostate: a report of two casesHeidi Talvitie, Kristina Aström, Olle Larsson, et al.
Pathology International|April 14, 2025
The Role of Artificial Intelligence in the Evaluation of Prostate PathologyLars Egevad, Andrea Camilloni, Brett Delahunt, et al.
Pathology|October 19, 2020
Benign mimics of prostate cancerLars Egevad, Brett Delahunt, Bungo Furusato, et al.
European Urology|January 15, 2018
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test PotentialPeter Ström, Tobias Nordström, Markus Aly, et al.
Carcinogenesis|May 23, 2002
Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factorsKari Hemminki, Yongwen Jiang, Xin Ma, et al.
Virchows Archiv : an International Journal of Pathology|April 10, 2003
Overexpression of IGBFB2 is a marker for malignant transformation in prostate epitheliumElin Richardsen, Tanja Ukkonen, Tone Bjørnsen, et al.
Analytical and Quantitative Cytology and Histology|May 1, 2009
Expression of immunomodulating genes in prostate cancer and benign prostatic tissueAnca Reschner, Helena Harlin, Brett Laven, et al.
BJU International|July 24, 2014
Upper limit of cancer extent on biopsy defining very low-risk prostate cancerOla Bratt, Yasin Folkvaljon, Stacy Loeb, et al.
Pageof 38